Dabigatran does not prolong the QT interval with supratherapeutic exposure: A thorough qt study in healthy subjects

Clinical Drug Investigation

Volumn 33, Issue 5, 2013, Pages 333-342

  Ring, Arne ^a,b   Rathgen, Karin ^a   Stangier, Joachim ^a   Reilly, Paul ^c   Clemens, Andreas ^a   Friedman, Jeffrey ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; MOXIFLOXACIN; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLEEDING; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; FEMALE; HEART ELECTROPHYSIOLOGY; HEART RATE; HEART RATE VARIABILITY; HEARTBURN; HEMATOMA; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MENORRHAGIA; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTITHROMBINS; BENZIMIDAZOLES; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; FEMALE; GERMANY; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PYRIDINES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84877040250     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0058-0     Document Type: Article

References (42)

1. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008;29(2):155-65.
2. Hylek EM. The need for new oral anticoagulants in clinical practice. J Cardiovasc Med (Hagerstown). 2009;10(8):605-9.
3. Maegdefessel L, Spin JM, Azuma J, et al. New options with dabigatran etexilate in anticoagulant therapy. Vasc Health Risk Manag. 2010;6:339-49.
4. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-99.
5. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303.
6. Weitz JI. New oral anticoagulants in development. Thromb Haemost. 2010;103(1):62-70.
7. Pradax™ Monograph. Health Canada. Available from URL: http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=79795. Accessed 4 Apr 2012.
8. Pradaxa® Summary of product characteristics. eMC. Available from URL: http://www.medicines.org.uk/EMC/medicine/20760/SPC/ Pradaxa+110+mg+hard+capsules/. Accessed 4 Apr 2012.
9. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949- 56.
10. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-85.
11. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009;101(1):77-85.
12. PRAZAXA (dabigatran etexilate) approved in Japan for stroke prevention in atrial fibrillation. Biotech pharma news. Available from URL: http://www.biotechpharmanews.com/news/37-jan-2011/634-boehringer-ingelheim- prazaxa-dabigatran-etexilate-approved-in-japan-for-stroke-prevention-in-atrial- fibrillation.html. Accessed 8 Feb 2012.
13. Pradaxa® prescribing information (online). US Food and Drug Administration. Available from URL: http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed 9 Jan 2012.
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875-6.
16. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58(1):32-45.
17. Food and Drug Administration H. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Fed Regist. 2005;70:61134-5.
18. Seidler R.W. Influence of BIBR 953 ZW (0.3 to 30 mg/kg IV) on cardiovascular function in anaesthetised pigs. Boehringer Ingelheim. 1998; Report no.: GP1998/031/PH2 (data on file).
19. Seidler RW. Effects of BIBR 953 ZW (0.01 to 10 μM) on action potential configuration in isolated guinea pig papillary muscle. Boehringer Ingelheim. 2005; Report no.: GP1999/073/PH2 (data on file).
20. Guth B. Influence of dabigatran (BIBR 953 ZW) on hERG-mediated potassium current in HEK293 cells. Boehringer Ingelheim. 2004; Report no.: GP2004/0341/PH2 (data on file).
21. Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd ed. Boca Raton: CRC Press/Taylor and Francis Group; 2003.
22. Zhang J, Machado SG. Statistical issues including design and sample size calculation in thorough QT/QTc studies. J Biopharm Stat. 2008;18(3):451-67.
23. Demolis JL, Kubitza D, Tenneze L, et al. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000;68(6):658-66.
24. Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf. 2008;31(1):67-77.
25. Matthys G, Park JW, McGuire S, et al. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol. 2010;70(1):24-33.
26. Schall R, Ring A. Statistical characterization of QT prolongation. J Biopharm Stat. 2010;20(3):543-62.
27. Ring A. Statistical models for heart rate correction of the QT interval. Stat Med. 2010;29(7-8):786-96.
28. Pattersor SD, Jones B, Zariffa N. Modeling and interpreting QTc prolongation in clinical pharmacology studies. Drug Inf J. 2005;39(4):437-45.
29. Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008;48(1):13-8.
30. Meng Z, Kringle R, Chen X, et al. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points. J Biopharm Stat. 2010;20(3):563-77.
31. Huettner S, Ring A, Sabo JP. No significant ECG effects are observed with therapeutic and supratherapeutic doses of tipranavir coadministered with ritonavir (TPV/r). In: Poster presentation at 47th interscience conference on antimicrobial agents and chemotherapy (ICAAC); 17-20 Sept 2007: Chicago, IL, USA.
32. Koenen-Bergmann M, Ring A. QT interval analyses from a placebo and positive controlled study evaluating the electrophysiological effects of tiotropium. In: International conference of the American Thoracic Society (ATS); 19-24 May 2006: San Diego, CA, USA.
33. Ring A. QT assessment when there is a heart rate increase. DIA Conference (Washington). Cardiovascular Safety in Drug development (oral presentation).
34. Sechaud R, Dumortier T, Balez S. Deferasirox does not induce QT/QTc-prolongation in healthy subjects. Int J Clin Pharmacol Ther. 2009;47(5):321-7.
35. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol. 2005;45(9):1038-47.
36. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004;2(9):1573-80.
37. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103-11.
38. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-95.
39. O'Mara E, Kasserra C, Huddlestone JR, et al. Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects. Antimicrob Agents Chemother. 2010;54(6):2448-54.
40. Walfridsson H, Johansson B, Englund A, et al. Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study. Clin Drug Investig. 2010;30(7):461-71.
41. Malik M, Farbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002;87(3):220-8.
42. Garnett CE, Zhu H, Malik M, et al. Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J. 2012;163(6):912-30.